Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality

Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality

Abstract Background Pneumocystis jirovecii pneumonia (PJP) is a life-threatening disease with increasing prevalence in patients with rheumatic disease. Trimethoprim/sulfamethoxazole (TMP/SMX) is an effective treatment for patients with rheumatic disease hospitalized for PJP. This study aimed to desc...

Full description

Bibliographic Details
Main Authors: Siyang Song, Yang Zhang, Jie Yu, Cuiying Xie, Yi Chen, Xingyu Zhang
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Infectious Diseases
Subjects:
Pneumocystis jirovecii pneumonia
Rheumatic disease
Trimethoprim
Sulfamethoxazole
Systemic lupus erythematosus
Inflammatory myopathy
Online Access:https://doi.org/10.1186/s12879-022-07940-z

Internet

https://doi.org/10.1186/s12879-022-07940-z

Similar Items